Literature DB >> 17565015

Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer.

Atsushi Horiike1, Hideharu Kimura, Kazuto Nishio, Fumiyoshi Ohyanagi, Yukitoshi Satoh, Sakae Okumura, Yuichi Ishikawa, Ken Nakagawa, Takeshi Horai, Makoto Nishio.   

Abstract

BACKGROUND: Somatic mutations of epidermal growth factor receptor (EGFR) are closely associated with an objective response to EGFR tyrosine kinase inhibitors. However, it is difficult to obtain sufficient tumor samples from patients with non-small cell lung cancer (NSCLC), so these diagnoses are often made using cytology procedures alone. The aim of this study was to detect EGFR mutations in transbronchial needle aspiration (TBNA) samples using both direct sequencing and a highly sensitive assay (Scorpions Amplified Refractory Mutation System; DxS; Manchester, UK) [ARMS], and to compare the sensitivity of these methods.
METHODS: We enrolled 94 patients (63 men and 31 women) with NSCLC in this study. Cytologic diagnoses were adenocarcinoma (n = 58), squamous cell carcinoma (n = 24), and other types of NSCLC (n = 12). We extracted DNA from the TBNA samples, and EGFR mutations were analyzed using both direct sequencing (exons 19 and 21) and the Scorpions ARMS method (E746 A750del and L858R).
RESULTS: Mutations were detected in 31 patients (33%; 14 women and 17 men). Of these, 23 patients had adenocarcinoma, 4 had squamous cell carcinoma, and 4 had other types of NSCLC. Direct sequencing detected 13 mutations (14%) in 13 patients (E746-A750del, n = 6; L858R, n = 7), and the Scorpions ARMS method detected 27 mutations (29%) in 27 patients (E746 A750del, n = 16; L858R, n = 11 patients).
CONCLUSIONS: Both methods detected EGFR mutations in TBNA samples, but Scorpions ARMS is more sensitive than direct sequencing.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17565015     DOI: 10.1378/chest.06-1673

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  29 in total

1.  DNA methylation profile during multistage progression of pulmonary adenocarcinomas.

Authors:  Jin-Haeng Chung; Hyun Ju Lee; Baek-Hui Kim; Nam-Yun Cho; Gyeong Hoon Kang
Journal:  Virchows Arch       Date:  2011-04-15       Impact factor: 4.064

2.  Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.

Authors:  Hua-Li Liu; Guang Han; Min Peng; Yi-Ming Weng; Jing-Ping Yuan; Gui-Fang Yang; Jin-Ming Yu; Qi-Bin Song
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-12-21

Review 3.  Advances in diagnostic bronchoscopy.

Authors:  Andrew R Haas; Anil Vachani; Daniel H Sterman
Journal:  Am J Respir Crit Care Med       Date:  2010-04-08       Impact factor: 21.405

4.  Predictive factors associated with gefitinib response in patients with advanced non-small-cell lung cancer (NSCLC).

Authors:  Lian Chen; Rui Chen; Zhe Zhu; Yichen Zhang; Zhengwei Wen; Yun Li; Xiaoming Li; Yuwen Luo; Liyu Ma; Shuguang Lin; Xin Chen
Journal:  Chin J Cancer Res       Date:  2014-08       Impact factor: 5.087

5.  Chromogenic in situ hybridization to detect EGFR gene copy number in cell blocks from fine-needle aspirates of non small cell lung carcinomas and lung metastases from colo-rectal cancer.

Authors:  Giovanni Simone; Anita Mangia; Andrea Malfettone; Vincenza Rubini; Michele Siciliano; Anna Di Benedetto; Irene Terrenato; Flavia Novelli; Marcella Mottolese
Journal:  J Exp Clin Cancer Res       Date:  2010-09-15

Review 6.  EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence.

Authors:  Anna Szumera-Ciećkiewicz; Włodzimierz T Olszewski; Andrzej Tysarowski; Dariusz M Kowalski; Maciej Głogowski; Maciej Krzakowski; Janusz A Siedlecki; Michał Wągrodzki; Monika Prochorec-Sobieszek
Journal:  Int J Clin Exp Pathol       Date:  2013-11-15

7.  Mutation detection of epidermal growth factor receptor and KRAS genes using the smart amplification process version 2 from formalin-fixed, paraffin-embedded lung cancer tissue.

Authors:  Yohei Miyamae; Kimihiro Shimizu; Yasumasa Mitani; Takuya Araki; Yuki Kawai; Masaru Baba; Seiichi Kakegawa; Masayuki Sugano; Kyoichi Kaira; Alexander Lezhava; Yoshihide Hayashizaki; Koujirou Yamamoto; Izumi Takeyoshi
Journal:  J Mol Diagn       Date:  2010-01-21       Impact factor: 5.568

8.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  J Thorac Oncol       Date:  2013-07       Impact factor: 15.609

9.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  Arch Pathol Lab Med       Date:  2013-04-03       Impact factor: 5.534

10.  EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).

Authors:  Anita Midha; Simon Dearden; Rose McCormack
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.